4-Antibody Appoints Dr. Richard Mason As New Chief Executive Officer
4-Antibody AG today announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschaeftsfuehrer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence.
Previously Dr. Mason was Senior Vice President Business Development at Cambridge Antibody Technology plc (CAT). As head of CAT’s business development team he was responsible for numerous transactions with major pharmaceutical and biotechnology companies including leading the negotiation of the original antibody co-discovery and co-development agreement with AstraZeneca which subsequently led to AstraZeneca’s acquisition of CAT for $1.3 billion. Dr. Mason qualified in medicine from the Medical College of St. Bartholomew’s Hospital, University of London. He trained in internal medicine and is a member of the Royal College of Physicians. He also holds a BSc degree in Immunology from University College London and an MBA from the Judge Business School, University of Cambridge. “We are delighted to appoint Richard as our CEO to lead 4-Antibody through the next exciting phase of its growth. His organisational leadership skills and experience in commercial dealmaking in the antibody space will be instrumental as we establish our technology as a new goldstandard for the discovery of fully human monoclonal antibody therapeutics”, stated Prof. Dr. Max Burger, Chairman of 4-Antibody’s Board.
Commenting on his appointment, Dr. Mason said, “I am very pleased to be joining this young and dynamic company with its world-class team of immunologists and molecular biologists. 4-Antibody has the most exciting and unencumbered platform for generating therapeutic antibodies in the industry today.”
About 4-Antibody Ltd.
4-Antibody is a privately owned Swiss biotech start-up company with headquarters in Basel, Switzerland and a wholly owned subsidiary in Jena, Germany. 4-Antibody is developing novel and proprietary technology platforms for the discovery and optimization of fully human monoclonal antibodies and is also developing a pipeline of fully human antibodies for severe and chronic diseases. For more information about 4-Antibody, visit our website at http://www.4-antibody.com.